GGrantIndex
← Leaderboards

Gary Fanger

Rise Therapeutics, Llc

Google Scholar ↗PubMed ↗ORCID ↗
$26,547,866
Attributed
$31,326,911
Total exposure
17
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $7.5M · FY2018–25
$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$31,326,911 · 17

By mechanism

R44$25,304,043 · 11
SB1$4,296,366 · 2
R43$1,297,344 · 3
UG3$429,158 · 1

Top collaborators

Most similar at Rise Therapeutics, Llc

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Probiotics”

Research focus

ProbioticsOralPharmaceutical PreparationsMucous MembraneMedicalDoseInflammatoryIntestinesCostImmuneMediatingCommercializationImmunologicsBiological MarkersBacteriaPreventResearch Clinical TestingProteinsMicrobiomeSmall Business Innovation Research GrantPropertyInvestmentsRecombinantsClinical Trials

Grant awards (43)

A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$952,967
R44 · FY2025 · AG · contact PI
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$827,713
R44 · FY2025 · AI
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis$704,565
SB1 · FY2025 · DK · contact PI
A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome$429,158
UG3 · FY2025 · DE · contact PI
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$995,869
R44 · FY2024 · DK
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$987,225
R44 · FY2024 · AG · contact PI
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$984,405
R44 · FY2024 · AI
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$956,049
R44 · FY2024 · AI
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$914,660
R44 · FY2024 · DK · contact PI
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis$673,379
SB1 · FY2024 · DK · contact PI
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$171,480
R44 · FY2024 · CA · contact PI
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)$1,026,596
R44 · FY2023 · AI
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$1,001,952
R44 · FY2023 · DK · contact PI
R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes$1,000,000
R44 · FY2023 · DK
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$983,580
R44 · FY2023 · DK
A Novel Probiotic for the Treatment of Sjogren's Syndrome$947,701
SB1 · FY2023 · DE · contact PI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$922,693
R44 · FY2023 · AI · contact PI
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$828,114
R44 · FY2023 · CA · contact PI
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis$494,488
R44 · FY2023 · AG · contact PI
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis$306,499
R44 · FY2023 · AI
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$1,049,717
R44 · FY2022 · CA · contact PI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$1,021,316
R44 · FY2022 · DK
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$1,000,000
R44 · FY2022 · AI · contact PI
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$973,438
R44 · FY2022 · AI · contact PI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$972,063
SB1 · FY2022 · DE · contact PI
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$459,043
R44 · FY2022 · DK · contact PI
A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis$360,624
R44 · FY2022 · DK · contact PI
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes$78,120
R44 · FY2022 · DK
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$30,223
R44 · FY2022 · DK · contact PI
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$24,936
R44 · FY2022 · DK · contact PI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis$1,000,000
R44 · FY2021 · AI · contact PI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$998,658
SB1 · FY2021 · DE · contact PI
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$913,769
R44 · FY2021 · AI · contact PI
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$895,539
R44 · FY2021 · DK · contact PI
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy$386,860
R44 · FY2021 · CA · contact PI
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection$957,796
R44 · FY2020 · AI · contact PI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$949,519
R44 · FY2020 · DE · contact PI
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$892,209
R44 · FY2020 · DK · contact PI
A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease$216,963
R43 · FY2020 · AI · contact PI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$956,644
R44 · FY2019 · DE · contact PI
A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease$299,931
R43 · FY2019 · AI · contact PI
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease$480,497
R43 · FY2018 · DK · contact PI
A novel Probiotic for Preventing and Treating Clostridium Difficile Pathogenesis$299,953
R43 · FY2018 · AI · contact PI